Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Liposarcoma 1

Interventions

Temozolomide 6Cyclophosphamide 5cabozantinib 4Vincristine 4fludarabine 3Radiotherapy 3Irinotecan 3liposomal doxorubicin 2irinotecan sucrosofate 2Zoledronic Acid 2Topotecan 2Specimen Handling 2PM 01183 2Ifosfamide 2Etoposide 2Eflornithine 2Drug Therapy 2Doxorubicin 2trilaciclib 1trifluridine tipiracil drug combination 1talazoparib 1silmitasertib 1romiplostim 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1naxitamab 1fluzoparib 1fludarabine phosphate 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sarcoma, Ewing × silmitasertib × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡